Giant-cell tumors of bone: an analysis of 87 cases.
We reviewed 87 patients with giant-cell tumor treated between 1992 and 2001. The mean follow-up was 62 (28-138) months. Fifty-six lesions were treated with intralesional curettage with adjunctive phenol treatment and reconstructed with autograft and allograft. Thirty-one lesions were treated with wide resection and reconstructed with prosthesis, osteochondral allograft, or alloprosthetic composite. Overall recurrence was 12%. Recurrence rate after curettage was 18% and 3% after wide excision. Complication rate after wide excision was higher than that after curettage. Functional outcome was evaluated using the Enneking scoring system. Average rating was 86% for the lower extremity and 83% for the upper extremity. The overall satisfactory rate was 88%.
Su
Yu-Ping
YP
Department of Orthopaedics and Traumatology, Veterans General Hospital, 201, Sec. 2, Shih-Pai Road, 112, Taipei, Taiwan, ROC.
Chen
Wei-Ming
WM
Chen
Tain-Hsiung
TH
D000293:Adolescent; D000328:Adult; D000368:Aged; D016025:Bone Transplantation; D016009:Chi-Square Distribution; D003475:Curettage; D005260:Female; D018212:Giant Cell Tumor of Bone / Q000601:surgery*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D019736:Prostheses and Implants; D016896:Treatment Outcome